SCHEMBL4708464

SCHEMBL4708464

CCn1nc(-c2ccccc2)c(C(N)=O)c(Nc2cccc(C#N)c2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.55
ACHE P22303 1/20 0.52
BACE1 P56817 1/20 0.52
PDE4A P27815 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
TP53 P04637 2/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 1/20 0.44
CSF1R P07333 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168526 0.97 PDE4B (0.55) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4708156 0.92 PDE4B (0.59) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4708376 0.91 PDE4B (0.66) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4708499 0.87 PDE4B (0.51) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL1652093 0.84 PDE4B (0.56) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4707585 0.83 PDE4B (0.55) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4708025 0.83 PDE4B (0.55) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4706044 0.83 PDE4B (0.55) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4705545 0.82 PDE4B (0.54) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL3027319 0.82 PDE4B (0.54) PDE4BACHEBACE1PDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US claimed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US claimed
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885ACHE 51/4885BACE1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.